Table 1.
Result of network meta-analysis and pairwise meta-analysis for bone mineral density (BMD) percentage change at lumbar spine (A), total hip (B), and distal radius (C).
| A. Lumbar Spine | |||||||||
| VitD | −6.17 (−10.10, −2.24) | ||||||||
| −9.83 (−14.87, −4.80) | Fluoride | 4.52 (0.89, 8.15) | 8.98 (7.01, 10.95) | ||||||
| −7.28 (−12.18, −2.37) | 2.55 (−0.86, 5.97) | SrRan | 0.90 (−1.53, 3.33) | 6.88 (−0.14, 13.89) | |||||
| −2.28 (−6.85, 2.29) | 7.55 (4.62, 10.49) | 5.00 (2.30, 7.69) | Calcitonin | −4.49 (−5.81, −3.16) | −1.90 (−2.75, −1.05) | 1.17 (0.46, 1.87) | |||
| −8.71 (−13.23, −4.18) | 1.13 (−1.74, 4.00) | −1.43 (−4.05, 1.20) | −6.43 (−8.21, −4.64) | PTH | 1.20 (−0.39, 2.79) | 5.42 (1.02, 9.83) | 7.45 (6.59, 8.31) | ||
| −2.31 (−6.99, 2.36) | 7.52 (4.41, 10.62) | 4.96 (2.08, 7.84) | −0.03 (−2.32, 2.25) | 6.39 (4.19, 8.59) | SERM | −3.86 (−6.87, −0.84) | 1.81 (1.04, 2.58) | ||
| −4.27 (−9.24, 0.71) | 5.56 (2.01, 9.11) | 3.01 (−0.34, 6.36) | −1.99 (−4.84, 0.86) | 4.44 (1.65, 7.23) | −1.96 (−4.98, 1.07) | HRT | −4.60 (−6.17, −3.02) | 4.77 (2.97, 6.57) | |
| −8.14 (−13.24, −3.04) | 1.69 (−1.99, 5.38) | −0.86 (−4.35, 2.63) | −5.86 (−8.84, −2.88) | 0.57 (−2.13, 3.26) | −5.82 (−9.01, −2.63) | −3.87 (−7.49, −0.25) | mAb | 8.25 (−1.65, 18.15) | |
| −6.20 (−10.49, −1.91) | 3.63 (0.10, 6.27) | 1.08 (−1.29, 3.45) | −3.92 (−5.48, −2.36) | 2.51 (1.07, 3.95) | −3.88 (−5.74, −2.03) | −1.93 (−4.44, 0.58) | 1.94 (−0.81, 4.69) | BP | 6.06 (5.69, 6.44) |
| −0.38 (−4.75, 3.99) | 9.45 (6.89, 12.01) | 6.90 (4.62, 9.17) | 1.90 (0.43, 3.36) | 8.32 (6.99, 9.66) | 1.93 (0.15, 3.72) | 3.89 (1.41, 6.37) | 7.76 (5.10, 10.41) | 5.82 (5.00, 6.63) | Placebo |
| B. Total Hip | |||||||||
| VitD | −2.20 (−4.20, −0.20) | ||||||||
| −0.40 (−4.78, 4.00) | Fluoride | −2.03 (−8.01, 3.94) | 1.57 (0.92, 2.21) | ||||||
| −4.39 (−8.91, 0.12) | −4.00 (−6.33, −1.67) | SrRan | 1.40 (−0.47, 3.27) | 5.76 (0.87, 10.66) | |||||
| −0.17 (−4.46, 4.12) | 0.22 (−1.66, 2.11) | 4.22 (2.05, 6.39) | Calcitonin | 0.10 (−0.24, 0.44) | −1.10 (−1.82, −0.38) | 1.24 (0.71, 1.77) | |||
| −1.16 (−5.41, 3.08) | −0.77 (−2.53, 0.99) | 3.23 (1.17, 5.28) | −0.99 (−2.45, 0.47) | PTH | −1.20 (−1.80, −0.60) | 1.23 (−0.96, 3.43) | 1.59 (0.97, 2.21) | ||
| −0.70 (−5.17, 3.76) | −0.31 (−2.57, 1.95) | 3.69 (1.19, 6.19) | −0.53 (−2.62, 1.56) | 0.46 (−1.51, 2.44) | SERM | −1.00 (−1.72, −0.28) | 1.73 (1.45, 2.01) | ||
| −2.42 (−6.98, 2.14) | −2.03 (−4.47, 0.42) | 1.97 (−0.70, 4.64) | −2.25 (−4.53, 0.04) | −1.26 (−3.44, 0.93) | −1.72 (−4.32, 0.88) | HRT | 0.19 (−1.03, 1.41) | 3.92 (2.46, 5.38) | |
| −3.50 (−8.15, 1.16) | −3.10 (−5.70, −0.50) | 0.90 (−1.91, 3.70) | −3.32 (−5.74, −0.90) | −2.33 (−4.41, −0.25) | −2.79 (−5.54, −0.04) | −1.07 (−3.98, 1.83) | mAb | 6.80 (6.56, 7.04) | |
| −2.20 (−6.30, 1.90) | −1.80 (−3.35, −0.26) | 2.19 (0.31, 4.07) | −2.03 (−3.28, −0.78) | −1.04 (−2.10, 0.03) | −1.50 (−3.26, 0.26) | 0.22 (−1.76, 2.20) | 1.29 (−0.91, 3.50) | BP | 3.72 (2.83, 4.61) |
| 1.26 (−2.90, 5.41) | 1.65 (0.18, 3.12) | 5.65 (3.83, 7.46) | 1.43 (0.22, 2.64) | 2.42 (1.43, 3.41) | 1.96 (0.22, 3.70) | 3.68 (1.70, 5.65) | 4.75 (2.61, 6.90) | 3.46 (2.83, 4.08) | Placebo |
| C. Distal Radius | |||||||||
| VitK | 1.70 (1.05, 2.35) | −3.50 (−4.16, −2.84) | −3.90 (−4.63, −3.17) | −1.49 (−2.14, −0.84) | 1.29 (0.67, 1.92) | ||||
| 1.47 (−1.83, 4.76) | VitD | −5.20 (−5.72, −4.68) | −5.60 (−6.22, −4.98) | −3.10 (−3.67, −2.53) | −0.30 (−0.84, 0.24) | ||||
| −0.91 (−4.58, 2.75) | −2.38 (−6.50, 1.74) | Fluoride | 2.01 (−2.46, 6.47) | ||||||
| −3.73 (−7.03, −0.44) | −5.20 (−8.74, −1.66) | −2.82 (−6.94, 1.30) | Calcitonin | −0.40 (−1.02, 0.22) | 2.10 (1.53, 2.67) | 4.90 (4.36, 5.44) | |||
| 3.31 (0.08, 6.53) | 1.84 (−1.90, 5.57) | 4.22 (0.68, 7.76) | 7.04 (3.30, 10.77) | PTH | −3.62 (−4.75, −2.48) | −7.80 (−9.70, −5.90) | −1.03 (−5.89, 3.83) | ||
| 0.21 (−4.16, 4.57) | −1.26 (−6.01, 3.49) | 1.12 (−3.42, 5.66) | 3.94 (−0.82, 8.69) | −3.10 (−7.36, 1.16) | SERM | 0.70 (−0.13, 1.53) | |||
| −4.13 (−7.45, −0.81) | −5.60 (−9.16, −2.04) | −3.21 (−7.35, 0.92) | −0.40 (−3.96, 3.16) | −7.44 (−11.19, −3.68) | −4.34 (−9.11, 0.43) | HRT | 2.50 (1.84, 3.16) | 5.30 (4.66, 5.94) | |
| −0.34 (−4.61, 3.94) | −1.81 (−6.48, 2.87) | 0.58 (−3.94, 5.09) | 3.39 (−1.28, 8.07) | −3.64 (−6.45, −0.84) | −0.54 (−5.65, 4.56) | 3.79 (−0.89, 8.48) | mAb | ||
| −1.59 (−4.04, 0.86) | −3.06 (−6.15, 0.02) | −0.68 (−3.77, 2.41) | 2.14 (−0.95, 5.22) | −4.90 (−7.34, −2.46) | −1.80 (−5.70, 2.10) | 2.54 (−0.57, 5.65) | −1.26 (−4.97, 2.46) | BP | 2.22 (1.72, 2.72) |
| 0.91 (−1.53, 3.34) | −0.56 (−3.64, 2.52) | 1.82 (−0.91, 4.55) | 4.64 (1.56, 7.72) | −2.40 (−4.65, −0.15) | 0.70 (−2.92, 4.32) | 5.04 (1.93, 8.14) | 1.24 (−2.35, 4.84) | 2.50 (1.06, 3.94) | Placebo |
Results of network meta-analysis (mixed comparison; lower-left portion) and pairwise meta-analysis (direct comparison; upper-right portion) for percentage change in bone mineral density (BMD) from baseline at distal radius (RU) in postmenopausal women with osteoporosis. Estimates are presented as weighted mean difference (WMD) and 95% confidence interval (CI; in parentheses). Comparisons between treatments should be read from left to right. The estimate of treatment effectiveness is located at the intersection of the column-defining treatment and the row-defining treatment. A WMD above 0 favors the column-defining treatment of the mixed comparison. Abbreviation: BP, bisphosphonate; HRT, hormone replacement therapy; mAb, monoclonal antibody; PTH, parathyroid hormone; SERM, selective estrogen receptor modulator; VitD, vitamin D; VitK, vitamin K.